Anyang

Researchers are evaluating the effectiveness of a house dust mite (HDM) sublingual immunotherapy (SLIT) tablet compared to a placebo in Chinese participants aged 12 to 65 years who have HDM allergic rhinitis or rhinoconjunctivitis, with or without asthma. This phase III trial aims to assess symptom control by measuring the total combined rhinitis score over the last 4 weeks of treatment. The study is designed as a randomized, double-blind, placebo-controlled, multi-site trial conducted in China. Participants will receive either the HDM SLIT-tablet, taken once daily, or a matching placebo tablet daily during the treatment period, which lasts between 24 and 28 weeks. The HDM SLIT-tablet is also known as Acarizax or Odactra. The study compares these two groups to evaluate the tablet's efficacy in reducing allergy symptoms. Throughout the study, participants will be monitored for symptom severity using the total combined rhinitis score during a primary efficacy assessment period of 4 weeks, starting 24 weeks after treatment begins. Safety and lung function will also be assessed to ensure participants meet eligibility and to monitor responses. The total participation time includes screening, treatment, and assessment phases lasting up to 28 weeks.

Researchers are evaluating the use of single versus double Perclose Proglide devices for closing the access site during transfemoral transcatheter aortic valve replacement (TAVR) in patients with severe aortic stenosis. TAVR is a minimally invasive treatment option for these patients and has shown safety and effectiveness across various risk groups. Proper closure of the vascular access site is crucial because vascular complications can lead to serious adverse outcomes such as bleeding, kidney failure, and increased mortality. The study aims to compare the clinical outcomes and potential benefits of using a single closure device versus the commonly used double device technique. This is a prospective, multicenter, randomized controlled trial involving patients scheduled for transfemoral TAVR who meet specific criteria. Participants are randomized to receive vascular closure using either a single Perclose Proglide device or a double device technique. The Perclose system works by deploying sutures before dilating the artery to allow closure of the large access site after valve delivery. The study evaluates the access site closure during the initial hospital stay and includes follow-up assessments. During the study, participants undergo planned evaluations including monitoring for vascular complications defined by established criteria. The primary outcome is the rate of major and minor vascular complications at the access site during hospitalization. Secondary outcomes include complication rates at 30 days, bleeding events, need for additional interventions, device failure, time to hemostasis, and length of hospital stay. Safety and adherence to the protocol are closely monitored throughout the study period.